Ondokuz Mayıs Üniversitesi Tıp Fakültesi, Genel Cerrahi Anabilim Dalı, Kurupelit 055100, Samsun, Turkey.
Singapore Med J. 2011 Apr;52(4):289-98.
The aims of the present study were to define the prognostic factors for locoregional recurrence (LRR) and survival in stage IIIC breast carcinoma as well as to examine the impact of adjuvant radiotherapy on the outcome of the disease.
The records of 586 consecutive patients with stage IIIC breast carcinoma who underwent modified radical mastectomy were evaluated, and the prognostic factors for LRR and survival were analysed. Survival curves were generated using the Kaplan-Meier method, and multivariate analysis was performed using the Cox proportional hazard model.
Five-year LRR and survival of stage IIIC breast carcinoma were 15 percent and 41.3 percent, respectively. Five-year LRR was significantly lower and five-year survival was significantly higher for all patients as well as for T1-2 patients with one to three apical node involvements who were treated with adjuvant radiotherapy. In multivariate analysis, apical node involvement, age below 35 years, T4 tumour, grade 3, extracapsular extension and lymphovascular invasion decreased survival, whereas adjuvant tamoxifen and adjuvant radiotherapy (risk ratio [RR] 0.51, 95 percent confidence interval [CI] 0.39-0.67) increased survival. Adjuvant radiotherapy was the sole independent factor that was found to be significantly associated with decreased LRR (RR 0.25, 95 percent CI 0.16-0.38).
Radiotherapy decreased LRR and increased survival significantly in all stage IIIC patients and in the subgroup of T1-2 patients with one to three apical node involvements. Thus, it should be considered in the treatment of stage IIIC breast carcinoma.
本研究旨在确定 IIIC 期乳腺癌局部区域复发(LRR)和生存的预后因素,并探讨辅助放疗对疾病结局的影响。
评估了 586 例连续接受改良根治性乳房切除术的 IIIC 期乳腺癌患者的记录,并分析了 LRR 和生存的预后因素。采用 Kaplan-Meier 法生成生存曲线,采用 Cox 比例风险模型进行多因素分析。
IIIC 期乳腺癌的 5 年 LRR 和生存分别为 15%和 41.3%。所有患者以及 T1-2 期、有 1-3 个 apical 淋巴结受累、接受辅助放疗的患者,5 年 LRR 明显较低,5 年生存率明显较高。多因素分析显示,apical 淋巴结受累、年龄<35 岁、T4 肿瘤、G3 级、包膜外侵犯和脉管侵犯降低生存,而辅助他莫昔芬和辅助放疗(风险比[RR]0.51,95%置信区间[CI]0.39-0.67)增加生存。辅助放疗是唯一与 LRR 显著相关的独立因素(RR 0.25,95%CI 0.16-0.38)。
放疗显著降低了所有 IIIC 期患者和 T1-2 期、有 1-3 个 apical 淋巴结受累的患者亚组的 LRR,并提高了生存,因此应考虑在 IIIC 期乳腺癌的治疗中应用。